Azra AI’s proprietary software which uses artificial intelligence (AI) and natural language processing to identify incidental lung nodules in medical reports — is expanding to include liver, kidney and adrenal, pancreatic and ovarian cancers, and aneurysms.
Now in use in more than 200 medical systems and hospitals across the country, Azra AI’s technology helps clinicians and medical teams identify suspicious findings that could lead to an earlier cancer diagnosis for patients, where treatment options allow patients to potentially be cured. These findings are detected in patients that receive imaging primarily for other healthcare illnesses or conditions, which explains the term “incidental.” Azra AI’s technology identifies cancers that often have no symptoms until the cancer is late-stage.